Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1983 Nov;38(11):840–844. doi: 10.1136/thx.38.11.840

Effects of verapamil on pulmonary haemodynamics during hypoxaemia, at rest, and during exercise in patients with chronic obstructive pulmonary disease.

S E Brown, G S Linden, R R King, G P Blair, D W Stansbury, R W Light
PMCID: PMC459673  PMID: 6648866

Abstract

The haemodynamic effects of intravenous verapamil at rest, during hypoxaemia, and during progressive exercise were evaluated in 10 patients with chronic obstructive lung disease. Verapamil produced significant decreases in the peak heart rate and systemic blood pressure during exercise but exercise capacity and pulmonary gas exchange at exhaustion were unaffected. There were no significant changes in pulmonary artery pressure or total pulmonary vascular resistance during exercise or during the breathing of either air or a hypoxic gas mixture at rest. No clinically useful benefit was found with verapamil in the dosage used in this group of patients and the value of calcium antagonists in the treatment of patients with chronic obstructive lung disease requires further clarification.

Full text

PDF
840

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atterhög J. H., Ekelund L. G. Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men. Eur J Clin Pharmacol. 1975 Jun 13;8(5):317–322. doi: 10.1007/BF00562656. [DOI] [PubMed] [Google Scholar]
  2. Bender F. Isoptin zur Behandlung der tachykarden Form des Vorhofflatterns. Med Klin. 1967 Apr 21;62(16):634–636. [PubMed] [Google Scholar]
  3. Brittinger W. D., Schwarzbeck A., Wittenmeier K. W., Twittenhoff W. D., Stegaru B., Huber W., Ewald R. W., von Henning G. E., Fabricius M., Strauch M. Klinisch-experimentelle Untersuchungen über die blutdrucksenkende Wirkung von Verapamil. Dtsch Med Wochenschr. 1970 Sep 11;95(37):1871–1877. doi: 10.1055/s-0028-1108744. [DOI] [PubMed] [Google Scholar]
  4. Camerini F., Alberti E., Klugmann S., Salvi A. Primary pulmonary hypertension: effects of nifedipine. Br Heart J. 1980 Sep;44(3):352–356. doi: 10.1136/hrt.44.3.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Crevey B. J., Dantzker D. R., Bower J. S., Popat K. D., Walker S. D. Hemodynamic and gas exchange effects of intravenous diltiazem in patients with pulmonary hypertension. Am J Cardiol. 1982 Feb 18;49(3):578–583. doi: 10.1016/s0002-9149(82)80015-5. [DOI] [PubMed] [Google Scholar]
  6. Davidson A., McMurtry I., Reeves J. T. Pulmonary vascular effects of verapamil. Am Heart J. 1978 Jun;95(6):810–811. doi: 10.1016/0002-8703(78)90515-x. [DOI] [PubMed] [Google Scholar]
  7. Ferlinz J., Easthope J. L., Aronow W. S. Effects of verapamil on myocardial performance in coronary disease. Circulation. 1979 Feb;59(2):313–319. doi: 10.1161/01.cir.59.2.313. [DOI] [PubMed] [Google Scholar]
  8. Fuller G. C., Nolan J. C. Prolyl hydroxylase activity in normal and diseased human liver. Proc Soc Exp Biol Med. 1976 Jan;151(1):61–64. doi: 10.3181/00379727-151-39143. [DOI] [PubMed] [Google Scholar]
  9. Furlanello F., Piccolo E., Disertori M., Trevi G. P., Lanzetta T., Miori Terapia antiaritmica con il verapamil per infusione endovenosa. Minerva Med. 1975 May 26;66(39):1887–1903. [PubMed] [Google Scholar]
  10. Landmark K., Refsum A. M., Simonsen S., Storstein O. Verapamil and pulmonary hypertension. Acta Med Scand. 1978;204(4):299–302. doi: 10.1111/j.0954-6820.1978.tb08443.x. [DOI] [PubMed] [Google Scholar]
  11. McMurtry I. F., Davidson A. B., Reeves J. T., Grover R. F. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res. 1976 Feb;38(2):99–104. doi: 10.1161/01.res.38.2.99. [DOI] [PubMed] [Google Scholar]
  12. McMurtry I. F., Reeves J. T., Will D. H., Grover R. F. Reduction of bovine pulmonary hypertension by normoxia, verapamil and hexoprenaline. Experientia. 1977 Sep 15;33(9):1192–1194. doi: 10.1007/BF01922322. [DOI] [PubMed] [Google Scholar]
  13. Parsons W. B. Osteopathy. Can Med Assoc J. 1982 Feb 1;126(3):231–231. [PMC free article] [PubMed] [Google Scholar]
  14. Simonneau G., Escourrou P., Duroux P., Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med. 1981 Jun 25;304(26):1582–1585. doi: 10.1056/NEJM198106253042606. [DOI] [PubMed] [Google Scholar]
  15. Singh B. N., Roche A. H. Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J. 1977 Nov;94(5):593–599. doi: 10.1016/s0002-8703(77)80128-2. [DOI] [PubMed] [Google Scholar]
  16. Suggett A. J., Mohammed F. H., Barer G. R. Angiotensin, hypoxia, verapamil and pulmonary vessels. Clin Exp Pharmacol Physiol. 1980 May-Jun;7(3):263–274. doi: 10.1111/j.1440-1681.1980.tb00070.x. [DOI] [PubMed] [Google Scholar]
  17. Thorens S., Haeusler G. Effects of some vasodilators on calcium translocation in intact and fractionated vascular smooth muscle. Eur J Pharmacol. 1979 Feb 15;54(1-2):79–91. doi: 10.1016/0014-2999(79)90410-2. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES